Coverage
Filings
| Filing | Date |
|---|---|
| Shingrix 18+ at risk China filing review accepted | 6 Feb 2024 |
| FDA accepts Arexvy filing for adults 50-59 at risk | 6 Feb 2024 |
| Statement: Zantac (ranitidine) litigation | 1 Feb 2024 |
| Total Voting Rights | 1 Feb 2024 |
| Director/PDMR Shareholding | 1 Feb 2024 |
| Final Results | 31 Jan 2024 |
| European Commission authorises Omjjara in the EU | 29 Jan 2024 |
| EMA accepts Arexvy filing for adults 50-59 at risk |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 29 Jan 2024 |
| Director/PDMR Shareholding | 19 Jan 2024 |
| GSK completes sale of shares in Haleon plc | 17 Jan 2024 |
| Director/PDMR Shareholding | 17 Jan 2024 |
| Director/PDMR Shareholding | 16 Jan 2024 |